These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
290 related items for PubMed ID: 22577855
1. The anti-tumor performance of docetaxel liposomes surface-modified with glycyrrhetinic acid. Li J, Xu H, Ke X, Tian J. J Drug Target; 2012 Jun; 20(5):467-73. PubMed ID: 22577855 [Abstract] [Full Text] [Related]
2. A wogonin-loaded glycyrrhetinic acid-modified liposome for hepatic targeting with anti-tumor effects. Tian J, Wang L, Wang L, Ke X. Drug Deliv; 2014 Nov; 21(7):553-9. PubMed ID: 24215357 [Abstract] [Full Text] [Related]
3. Transporter occluded-state conformation-induced endocytosis: Amino acid transporter ATB0,+-mediated tumor targeting of liposomes for docetaxel delivery for hepatocarcinoma therapy. Luo Q, Gong P, Sun M, Kou L, Ganapathy V, Jing Y, He Z, Sun J. J Control Release; 2016 Dec 10; 243():370-380. PubMed ID: 27810556 [Abstract] [Full Text] [Related]
4. Glycyrrhetinic acid-graft-hyaluronic acid conjugate as a carrier for synergistic targeted delivery of antitumor drugs. Zhang L, Yao J, Zhou J, Wang T, Zhang Q. Int J Pharm; 2013 Jan 30; 441(1-2):654-64. PubMed ID: 23117024 [Abstract] [Full Text] [Related]
5. Hepatocellular Carcinoma Targeting and Pharmacodynamics of Paclitaxel Nanoliposomes Modified by Glycyrrhetinic Acid and Ferric Tetroxide. Zhao L, Liang L, Guo M, Li M, Yu X, Wang Y, Wang Y. Curr Top Med Chem; 2021 Oct 05; 21(14):1268-1284. PubMed ID: 34620053 [Abstract] [Full Text] [Related]
6. Development of 11-DGA-3-O-Gal-Modified Cantharidin Liposomes for Treatment of Hepatocellular Carcinoma. Zhou L, Zou M, Zhu K, Ning S, Xia X. Molecules; 2019 Aug 24; 24(17):. PubMed ID: 31450608 [Abstract] [Full Text] [Related]
7. Cellular uptake mechanism and clearance kinetics of fluorescence-labeled glycyrrhetinic acid and glycyrrhetinic acid-modified liposome in hepatocellular carcinoma cells. Sun Y, Lu J, Yan D, Shen L, Hu H, Chen D. Environ Toxicol Pharmacol; 2017 Jul 24; 53():46-56. PubMed ID: 28501784 [Abstract] [Full Text] [Related]
8. Doxorubicin-loaded glycyrrhetinic acid modified recombinant human serum albumin nanoparticles for targeting liver tumor chemotherapy. Qi WW, Yu HY, Guo H, Lou J, Wang ZM, Liu P, Sapin-Minet A, Maincent P, Hong XC, Hu XM, Xiao YL. Mol Pharm; 2015 Mar 02; 12(3):675-83. PubMed ID: 25584860 [Abstract] [Full Text] [Related]
9. Hepatocellular carcinoma-targeted effect of configurations and groups of glycyrrhetinic acid by evaluation of its derivative-modified liposomes. Sun Y, Dai C, Yin M, Lu J, Hu H, Chen D. Int J Nanomedicine; 2018 Mar 02; 13():1621-1632. PubMed ID: 29588589 [Abstract] [Full Text] [Related]
10. Anti-tumor therapy of glycyrrhetinic acid targeted liposome co-delivery of doxorubicin and berberine for hepatocellular carcinoma. Xu N, Wu J, Wang W, Sun S, Sun M, Bian Y, Zhang H, Liu S, Yu G. Drug Deliv Transl Res; 2024 Sep 02; 14(9):2386-2402. PubMed ID: 38236508 [Abstract] [Full Text] [Related]
11. Glycyrrhetinic Acid and TAT Peptide Modified Dual-functional Liposomes for Treatment of Hepatocellular Cancer. Huang S, Ren D, Wu X, Li M, Yu X, Nie X, Wang Y, Wang Y. Curr Top Med Chem; 2020 Sep 02; 20(27):2493-2505. PubMed ID: 32703132 [Abstract] [Full Text] [Related]
12. Glycyrrhetinic Acid-Mediated Polymeric Drug Delivery Targeting the Acidic Microenvironment of Hepatocellular Carcinoma. Zhang J, Zhang M, Ji J, Fang X, Pan X, Wang Y, Wu C, Chen M. Pharm Res; 2015 Oct 02; 32(10):3376-90. PubMed ID: 26148773 [Abstract] [Full Text] [Related]
13. Glycyrrhetinic Acid Mediated Drug Delivery Carriers for Hepatocellular Carcinoma Therapy. Cai Y, Xu Y, Chan HF, Fang X, He C, Chen M. Mol Pharm; 2016 Mar 07; 13(3):699-709. PubMed ID: 26808002 [Abstract] [Full Text] [Related]
14. Solid dispersion and effervescent techniques used to prepare docetaxel liposomes for lung-targeted delivery system: in vitro and in vivo evaluation. Zhao L, Wei Y, Li W, Liu Y, Wang Y, Zhong X, Yu Y. J Drug Target; 2011 Apr 07; 19(3):171-8. PubMed ID: 20429774 [Abstract] [Full Text] [Related]
15. A pH-responsive α-helical cell penetrating peptide-mediated liposomal delivery system. Zhang Q, Tang J, Fu L, Ran R, Liu Y, Yuan M, He Q. Biomaterials; 2013 Oct 07; 34(32):7980-93. PubMed ID: 23891517 [Abstract] [Full Text] [Related]
16. Preparation, characterization and uptake by primary cultured rat hepatocytes of liposomes surface-modified with glycyrrhetinic acid. Mao SJ, Bi YQ, Jin H, Wei DP, He R, Hou SX. Pharmazie; 2007 Aug 07; 62(8):614-9. PubMed ID: 17867558 [Abstract] [Full Text] [Related]
17. A novel glycyrrhetinic acid-modified oxaliplatin liposome for liver-targeting and in vitro/vivo evaluation. Chen J, Jiang H, Wu Y, Li Y, Gao Y. Drug Des Devel Ther; 2015 Aug 07; 9():2265-75. PubMed ID: 25945038 [Abstract] [Full Text] [Related]
18. RGD-modified pH-sensitive liposomes for docetaxel tumor targeting. Chang M, Lu S, Zhang F, Zuo T, Guan Y, Wei T, Shao W, Lin G. Colloids Surf B Biointerfaces; 2015 May 01; 129():175-82. PubMed ID: 25851582 [Abstract] [Full Text] [Related]
19. Dual-Ligand-Functionalized Liposomes Based on Glycyrrhetinic Acid and cRGD for Hepatocellular Carcinoma Targeting and Therapy. Qiu M, Wang J, Bai J, Li X, Tian C, Liu Z, Zheng C, Clark AR, Cheng X, Liao X, Wu S, Lee RJ, Zhou X. Mol Pharm; 2023 Apr 03; 20(4):1951-1963. PubMed ID: 36952242 [Abstract] [Full Text] [Related]
20. Glycyrrhetinic acid-modified poly(ethylene glycol)-b-poly(gamma-benzyl l-glutamate) micelles for liver targeting therapy. Huang W, Wang W, Wang P, Tian Q, Zhang C, Wang C, Yuan Z, Liu M, Wan H, Tang H. Acta Biomater; 2010 Oct 03; 6(10):3927-35. PubMed ID: 20438873 [Abstract] [Full Text] [Related] Page: [Next] [New Search]